bexarotene has been researched along with Mouth Neoplasms in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ba'th, F; Handley, N; Mathison, G; Nachbor, KM; Ondrey, FG; Rosas, RR; Wuertz, BR | 1 |
| Gudas, LJ; Osei-Sarfo, K | 1 |
| Gudas, LJ; Osei-Sarfo, K; Scognamiglio, T; Tang, XH; Urvalek, AM; Zhang, T | 1 |
3 other study(ies) available for bexarotene and Mouth Neoplasms
| Article | Year |
|---|---|
Preclinical evidence for pioglitazone and bexarotene combination in oral cancer chemoprevention.
Topics: Bexarotene; Chemoprevention; Head and Neck Neoplasms; Humans; Mouth Neoplasms; Pioglitazone; United States | 2022 |
Retinoids induce antagonism between FOXO3A and FOXM1 transcription factors in human oral squamous cell carcinoma (OSCC) cells.
Topics: Antineoplastic Agents; Bexarotene; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; Forkhead Box Protein O3; Gene Expression; Gene Knockdown Techniques; Histone Deacetylases; Humans; Mouth Neoplasms; Promoter Regions, Genetic; Retinoids; RNA, Messenger; Tretinoin | 2019 |
Combination of bexarotene and the retinoid CD1530 reduces murine oral-cavity carcinogenesis induced by the carcinogen 4-nitroquinoline 1-oxide.
Topics: 4-Nitroquinoline-1-oxide; Animals; Anticarcinogenic Agents; Benzoates; beta Catenin; Bexarotene; Carcinogenesis; Carcinogens; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Esophageal Neoplasms; Female; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mouth Neoplasms; Naphthols; Oxidative Stress; Reactive Oxygen Species; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoids; Tetrahydronaphthalenes; Triglycerides | 2014 |